Skip to main content

Table 3 Comparison of general information between two groups

From: Discovery and validation of PZP as a novel serum biomarker for screening lung adenocarcinoma in type 2 diabetes mellitus patients

General information

T2DM

T2DM + LAC

P value

Gender (male/female)

23/17

19/21

0.371

Hypoglycemic therapy (A/B)a

27/13

26/14

0.813

Age (years)

61.05 ± 9.78

64.68 ± 7.10

0.137

AFP (ng/ml)

2.70 ± 1.17

3.21 ± 1.57

0.101

CEA (ng/ml)

2.11 ± 1.09

3.27 ± 3.72

0.304

CA125 (U/ml)

9.50 ± 4.86

12.34 ± 15.66

0.693

CA199 (U/ml)

14.41 ± 10.44

27.51 ± 68.25

0.994

FPG (mmol/L)

7.95 ± 1.91

7.41 ± 2.55

0.287

  1. aA, insulin or insulin-dependent therapies; B, insulin-independent therapies or no treatment